Imugene Limited (ASX: IMU), a company specializing in immuno-oncology, has initiated the dosing of the first participant in a Phase 1b clinical trial utilizing azer-cel (an allogeneic off-the-shelf CD19 CAR T cell therapy) from Imugene's advanced facility in North Carolina. Azer-cel, currently under investigation in a multi-center Phase 1b trial for non-Hodgkin’s lymphoma (NHL), has shown promising safety and efficacy signals in the prior Phase 1 trial involving 84 patients across prominent U.S. centers.
The Phase 1b trial serves as a precursor for a potential Phase 2 registrational study in 2024, pending FDA agreement. The successful outcome of this trial could pave the way for a groundbreaking achievement, potentially making azer-cel the first approved allogeneic CAR T cell therapy for cancer. The company's focus on advancing this therapy marks a significant step towards developing an innovative treatment for blood cancer.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 20, 2024
Nov 20, 2024
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
